Skip to main content
Erschienen in:

13.08.2024 | Melanoma

Using Nomograms Wisely: Predicting Sentinel Node Positivity in Melanoma

verfasst von: Priscila Rojas-Garcia, MD, Bryan Ma, MD, Eva Lindell Jonsson, MD, PhD, Olivia Genereux, MD, Gregory McKinnon, MD, Thomas Brenn, MD, Golpira Elmi Assadzadeh, PhD, Claire Temple-Oberle, MD, MSc

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Four externally validated sentinel node biopsy (SNB) prediction nomograms exist for malignant melanoma that each incorporate different clinical and histopathologic variables, which can result in substantially different risk estimations for the same patient. We demonstrate this variability by using hypothetical melanoma cases.

Methods

We compared the MSKCC and MIA calculators. Using a random number generator, 300 hypothetical thin melanoma “patients” were created with varying age, tumor thickness, Clark level, location on the body, ulceration, melanoma subtype, mitosis, and lymphovascular invasion (LVI). The chi-square test was used to detect statistically significant differences in risk estimations between nomograms. Multivariate linear regression was used to determine the most relevant contributing pathologic features in cases where the predictions diverged by > 10%.

Results

Of 300 randomly generated cases, 164 were deleted as their clinical scenarios were unlikely. The MSKCC nomogram generally calculated a lower risk than the MIA (p < 0.001). The highest risk score attained for any “patient” using MSKCC calculator was 15% achieved in one of 136 patients (0.7%), whereas using the MIA nomogram, 58 of 136 patients (43%, p < 0.001) had predicted risk >15%. Regression analysis on patients with >10% difference between nomograms revealed LVI (26, p < 0.001), mitosis (14, p < 0.001), and melanoma subtype (8, p < 0.001) were the factors with high coefficients within MIA that were not present in MSKCC.

Conclusions

Nomograms are useful tools when predicting SNB risk but provide risk outputs that are quite sensitive to included predictors.
Literatur
1.
Zurück zum Zitat Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRefPubMedPubMedCentral Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25(4):894–902.CrossRefPubMed Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25(4):894–902.CrossRefPubMed
3.
Zurück zum Zitat Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.CrossRefPubMedPubMedCentral Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Grimes DA. The nomogram epidemic: resurgence of a medical relic. Ann Intern Med. 2008;149(4):273–5.CrossRefPubMed Grimes DA. The nomogram epidemic: resurgence of a medical relic. Ann Intern Med. 2008;149(4):273–5.CrossRefPubMed
6.
Zurück zum Zitat Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American joint committee on cancer staging system. Ann Surg Oncol. 2005;12(4):282–8.CrossRefPubMed Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American joint committee on cancer staging system. Ann Surg Oncol. 2005;12(4):282–8.CrossRefPubMed
7.
Zurück zum Zitat Chen LL, Nolan ME, Silverstein MJ, et al. The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer. 2009;115(21):5071–83.CrossRefPubMed Chen LL, Nolan ME, Silverstein MJ, et al. The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer. 2009;115(21):5071–83.CrossRefPubMed
8.
Zurück zum Zitat Lo SN, Ma J, Scolyer RA, et al. Improved Risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram. J Clin Oncol. 2020;38(24):2719.CrossRefPubMedPubMedCentral Lo SN, Ma J, Scolyer RA, et al. Improved Risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram. J Clin Oncol. 2020;38(24):2719.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Maurichi A, Miceli R, Eriksson H, et al. Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram. J Clin Oncol. 2020;38(14):1591.CrossRefPubMedPubMedCentral Maurichi A, Miceli R, Eriksson H, et al. Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram. J Clin Oncol. 2020;38(14):1591.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(4):364–76.CrossRefPubMed Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(4):364–76.CrossRefPubMed
11.
Zurück zum Zitat Stassen RC, Mulder EEAP, Mooyaart AL, et al. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: a multicenter prospective Dutch study. Eur J Surg Oncol. 2023;49(12):107249.CrossRefPubMed Stassen RC, Mulder EEAP, Mooyaart AL, et al. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: a multicenter prospective Dutch study. Eur J Surg Oncol. 2023;49(12):107249.CrossRefPubMed
12.
Zurück zum Zitat Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: a seer collaboration. JCO Precis Oncol. 2023;7:e2300044.CrossRefPubMedPubMedCentral Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: a seer collaboration. JCO Precis Oncol. 2023;7:e2300044.CrossRefPubMedPubMedCentral
Metadaten
Titel
Using Nomograms Wisely: Predicting Sentinel Node Positivity in Melanoma
verfasst von
Priscila Rojas-Garcia, MD
Bryan Ma, MD
Eva Lindell Jonsson, MD, PhD
Olivia Genereux, MD
Gregory McKinnon, MD
Thomas Brenn, MD
Golpira Elmi Assadzadeh, PhD
Claire Temple-Oberle, MD, MSc
Publikationsdatum
13.08.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15891-9

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.